VSV-IFNbeta-NIS

AXP000119.2 · Oncolytic virus

Platform
vesicular stomatitis virus (Indiana serotype, recombinant)
Originator
Mayo Clinic
Sponsor
Vyriad

Names

NameTypeSource
VSV-IFNbeta-NISpreferred namecurator
Voyager-V1brandncit
VSV-hIFNbeta-NIScodencit
VSV-IFNb-NISsynonymncit
VV1 ambiguoussynonymncit

Virus

Role
Oncolytic
Family
Rhabdoviridae
Virus
vesicular stomatitis Indiana virus (NCBI Taxonomy 11277)
Strain
Indiana, recombinant
Replication
replicating
Modifications
human IFN-beta and NIS cassettes inserted
Transgenes
IFNB1, SLC5A5
Route
intravenous
Source
evidence

Cross-references

NCI Thesaurus
C131580

Approvals

No regulatory approval recorded.

Clinical trials (7)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07510334VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell CarcinomaRecruitingPhase 22026-04-212033-08-0118Advanced Clear Cell Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8
NCT06508463Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell LymphomaRecruitingPhase 12024-01-052028-12-3121Anaplastic Large Cell Lymphoma; Mycosis Fungoides; Peripheral T Cell Lymphoma; Peripheral T-Cell Lymphoma, Not Otherwise Specified; Relapsed Anaplastic Large Cell Lymphoma; Relapsed Mycosis Fungoides; Relapsed Peripheral T-Cell Lymphoma
NCT04291105Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer PatientsActive not recruitingPhase 22020-04-242026-1087Colo-rectal Cancer; Head and Neck Squamous Cell Carcinoma; Melanoma
NCT03647163Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid TumorsActive not recruitingPhase 1/22019-04-092025-07-3133Neuroendocrine Carcinoma; Non Small Cell Lung Cancer; Renal Cell Carcinoma (RCC); Solid Tumor
NCT03120624VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial CancerActive not recruitingPhase 12017-09-152023-08-2934Metastatic Endometrial Carcinoma; Recurrent Endometrial Adenocarcinoma; Recurrent Endometrial Carcinoma; Recurrent Endometrial Clear Cell Adenocarcinoma; Recurrent Endometrial Endometrioid Adenocarcinoma; Recurrent Endometrial Mixed Cell Adenocarcinoma; Recurrent Endometrial Serous Adenocarcinoma; Recurrent Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinosarcoma; Stage IV Uterine Corpus Cancer AJCC v7
NCT03017820A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or LymphomaRecruitingPhase 12017-04-042028-12-3199B-Cell Non-Hodgkin Lymphoma; Histiocytic and Dendritic Cell Neoplasm; Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome; Recurrent Adult Acute Myeloid Leukemia; Recurrent Anaplastic Large Cell Lymphoma; Recurrent Angioimmunoblastic T-Cell Lymphoma; Recurrent Mycosis Fungoides; Recurrent Plasma Cell Myeloma; Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Recurrent T-Cell Non-Hodgkin Lymphoma; Refractory Acute Myeloid Leukemia; Refractory Anaplastic Large Cell Lymphoma; Refractory Angioimmunoblastic T-Cell Lymphoma; Refractory Mycosis Fungoides; Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified; Refractory Plasma Cell Myeloma; Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Refractory T-Cell Non-Hodgkin Lymphoma
NCT01042379I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingPhase 22010-03-012030-125000Angiosarcoma; Breast Cancer; Breast Neoplasms; Breast Tumors; Early-stage Breast Cancer; HER2-negative Breast Cancer; HER2-positive Breast Cancer; Hormone Receptor Negative Tumor; Hormone Receptor Positive Tumor; Locally Advanced Breast Cancer; TNBC - Triple-Negative Breast Cancer

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 41879562Longitudinal DCE MRI Vascular Textures: Radiologic and Biologic Insights for pCR Prediction in HER2-Negative Breast Cancer.Radiology. Artificial intelligence2026cited by trial NCT01042379
PMID 42130226Outcomes After Intratumoral Delivery of Immunotherapy in Breast Cancer.Journal of surgical oncology2026name in abstract: Voyager-V1
PMID 42530945Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial.JAMA oncology2026cited by trial NCT01042379
PMID 42545411Surgical Management of Young Women with High-Risk Breast Cancer Receiving Neoadjuvant Systemic Therapy on the I-SPY2 Trial.Annals of surgical oncology2026cited by trial NCT01042379
PMID 42619946Circulating tumor DNA concentration at diagnosis is a modifiable prognostic factor for distant metastatic recurrence in patients with high-risk breast cancer receiving neoadjuvant therapy.medRxiv : the preprint server for health sciences2026cited by trial NCT01042379
PMID 42811224Separating Ranking Signal, Incremental Feature Value, and Evaluation-Induced Optimism in Breast MRI Treatment-Effect Analysis: Foundation Model and Radiomic Representations.Journal of imaging informatics in medicine2026cited by trial NCT01042379
PMID 42911610Rilvegostomig Plus Trastuzumab-Deruxtecan for Early-Stage Breast Cancer: The I-SPY2.2 Randomized Clinical Trial.JAMA oncology2026cited by trial NCT01042379
PMID 39158353Implementation and impact of an electronic patient reported outcomes system in a phase II multi-site adaptive platform clinical trial for early-stage breast cancer.Journal of the American Medical Informatics Association : JAMIA2025cited by trial NCT01042379
PMID 39625569Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer.Breast cancer research and treatment2025cited by trial NCT01042379
PMID 40526879Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial.JCO precision oncology2025cited by trial NCT01042379
PMID 40551254Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial.Breast cancer research : BCR2025cited by trial NCT01042379
PMID 40639409A two-stage dual-task learning strategy for early prediction of pathological complete response to neoadjuvant chemotherapy for breast cancer using dynamic contrast-enhanced magnetic resonance images.Physics in medicine and biology2025cited by trial NCT01042379
PMID 40679371Radiomics-based Machine Learning Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Using Physiologically Decomposed Diffusion-weighted MRI.Radiology. Imaging cancer2025cited by trial NCT01042379
PMID 40777112Detection of serum HER2 in patients treated with neratinib or trastuzumab: analysis of the I-SPY Trial.Frontiers in oncology2025cited by trial NCT01042379
PMID 38180338Breast Multiparametric MRI for Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer: The BMMR2 Challenge.Radiology. Imaging cancer2024cited by trial NCT01042379
PMID 38745646Circulating tumor DNA: from discovery to clinical application in breast cancer.Frontiers in immunology2024cited by trial NCT01042379
PMID 39277671Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.Nature medicine2024cited by trial NCT01042379
PMID 39277672Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.Nature medicine2024cited by trial NCT01042379
PMID 39613746Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial.Nature communications2024cited by trial NCT01042379
PMID 36898933Nodal peripheral T-cell lymphoma: Chemotherapy-free management, are we there yet?Blood reviews2023cited by trial NCT03017820
PMID 37029329Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial.Breast cancer research and treatment2023cited by trial NCT01042379
PMID 37325931Breast Conservation Surgery and Mastectomy Have Similar Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From 1462 Patients on the Prospective, Randomized I-SPY2 Trial.Annals of surgery2023cited by trial NCT01042379
PMID 37505107Effect of Longitudinal Variation in Tumor Volume Estimation for MRI-guided Personalization of Breast Cancer Neoadjuvant Treatment.Radiology. Imaging cancer2023cited by trial NCT01042379
PMID 38086377Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial.Cell reports. Medicine2023cited by trial NCT01042379
PMID 35175355Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma.Blood advances2022cited by trial NCT03017820
PMID 35623341Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.Cancer cell2022cited by trial NCT01042379
PMID 35993306Postneoadjuvant treatment for triple-negative breast cancer.Current opinion in oncology2022cited by trial NCT01042379
PMID 36069821Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial.JAMA surgery2022cited by trial NCT01042379
PMID 36456573Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.NPJ breast cancer2022cited by trial NCT01042379
PMID 34529000Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.JAMA oncology2021cited by trial NCT01042379
PMID 34741021RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer.Nature communications2021cited by trial NCT01042379
PMID 32031889MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2020cited by trial NCT01042379
PMID 32053137Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.JAMA oncology2020cited by trial NCT01042379
PMID 32450725Atezolizumab in the treatment of metastatic triple-negative breast cancer.Expert opinion on biological therapy2020cited by trial NCT01042379
PMID 32701140Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.JAMA oncology2020cited by trial NCT01042379
PMID 28851423The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.Breast cancer research : BCR2017cited by trial NCT01042379
PMID 27406346Adaptive Randomization of Neratinib in Early Breast Cancer.The New England journal of medicine2016cited by trial NCT01042379
PMID 27406347Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.The New England journal of medicine2016cited by trial NCT01042379
PMID 21796368Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial).Breast cancer research and treatment2012cited by trial NCT01042379
PMID 22198468Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).Breast cancer research and treatment2012cited by trial NCT01042379
PMID 22623692Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL.Radiology2012cited by trial NCT01042379
PMID 22649152Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2012cited by trial NCT01042379

Notes

Recombinant VSV expressing human interferon beta and the sodium iodide symporter; brand/development name Voyager-V1 (VV1). Mayo Clinic and Vyriad both sponsor trials. The IFN-beta-only predecessor (NCT01628640) is a separate program, VSV-hIFNbeta. Transgenes moved from targets to virus.tsv (spec 0.2).

How to cite

VSV-IFNbeta-NIS (AXP000119.2). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000119.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.